| Year |
Citation |
Score |
| 2020 |
Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu YJ, Chen YH, Golder V, Lateef A, Cho J, Navarra S, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Katsumata Y, ... ... Lofland JH, et al. Ab0384 Medication Use In Systemic Lupus Erythematosus – Data From A Multicentre Cohort Study Annals of the Rheumatic Diseases. 79: 1492-1493. DOI: 10.1136/Annrheumdis-2020-Eular.3007 |
0.337 |
|
| 2019 |
Kariburyo F, Xie L, Sah J, Li N, Lofland JH. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. Journal of Medical Economics. 1. PMID 31589081 DOI: 10.1080/13696998.2019.1678170 |
0.397 |
|
| 2019 |
Xie L, Kariburyo F, Sah J, Lofland JH, Nan L. Fri0201 Real World Medication Use In Incident Systemic Lupus Erythematosus And Lupus Nephritis Patients Annals of the Rheumatic Diseases. 78: 779-780. DOI: 10.1136/Annrheumdis-2019-Eular.543 |
0.375 |
|
| 2019 |
Touma Z, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar C, Costenbader K. Ab0486 Lack Of Consistent Standard Of Care In Systemic Lupus Erythematosus Patients In Real World Annals of the Rheumatic Diseases. 78: 1706-1706. DOI: 10.1136/Annrheumdis-2019-Eular.4392 |
0.376 |
|
| 2019 |
Costenbader K, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar C, Touma Z. Fri0256 Assessing The Prevalence And Use Of Validated Systemic Lupus Erythematosus Disease Activity Metrics In Real World Practice Annals of the Rheumatic Diseases. 78: 807-808. DOI: 10.1136/Annrheumdis-2019-Eular.4239 |
0.382 |
|
| 2018 |
Lin X, Lofland J, Zhang L, Lee K, Sloan S, Chamaa L, Marano C, Plevy S. P715 Opioid use in patients with inflammatory bowel disease Journal of Crohn's and Colitis. 12: S473-S473. DOI: 10.1093/Ecco-Jcc/Jjx180.842 |
0.339 |
|
| 2018 |
Lin X, Lofland J, Zhang L, Lee K, Sloan S, Chamaa L, Marano C, Plevy S. Sa1811 - Opioid use in Patients with Inflammatory Bowel Disease Gastroenterology. 154: S-404. DOI: 10.1016/S0016-5085(18)31635-4 |
0.341 |
|
| 2017 |
Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Preference and Adherence. 11: 947-958. PMID 28572722 DOI: 10.2147/Ppa.S133222 |
0.387 |
|
| 2017 |
Bolge SC, Eldridge HM, Lofland JH, Ravin C, Hart PJ, Ingham MP. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Preference and Adherence. 11: 661-669. PMID 28405158 DOI: 10.2147/Ppa.S121032 |
0.354 |
|
| 2015 |
Tkacz J, Brady BL, Meyer R, Lofland JH, Ruetsch C, Coelho-Prabhu N. An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease. Journal of Managed Care & Specialty Pharmacy. 21: 1064-76. PMID 26521118 DOI: 10.18553/Jmcp.2015.21.11.1064 |
0.405 |
|
| 2015 |
Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 57: 635-42. PMID 26053366 DOI: 10.1097/Jom.0000000000000461 |
0.312 |
|
| 2015 |
Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making. The Patient. PMID 25963447 DOI: 10.1007/S40271-015-0126-Z |
0.369 |
|
| 2015 |
Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences. 60: 2636-45. PMID 25939543 DOI: 10.1007/S10620-015-3675-Z |
0.361 |
|
| 2015 |
David G, Gunnarsson C, Lofland JH. Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease. Journal of Medical Economics. 18: 137-44. PMID 25335098 DOI: 10.3111/13696998.2014.978454 |
0.412 |
|
| 2015 |
Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. Journal of Medical Economics. 18: 12-28. PMID 25253504 DOI: 10.3111/13696998.2014.969434 |
0.313 |
|
| 2015 |
Lofland J, Johnson PT, Watkins A, White JC. Shared decision making among Patients with autoimmune conditions initiating Biologic Therapy: initial findings Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1753 |
0.306 |
|
| 2014 |
Tkacz J, Brady B, Meyer R, Lofland J, Prabhu NC, Ruetsch C. Inflammatory Bowel Disease Quality Measure Results in a Large National Plan Dataset: 2207 The American Journal of Gastroenterology. 109. DOI: 10.14309/00000434-201410002-02207 |
0.331 |
|
| 2014 |
David G, Mallow PJ, Cantu H, Lofland J. Su1316 Effects of Patient Annual Adherence of Biologics on Healthcare Resource Utilization for Patients With Inflammatory Bowel Disease Gastroenterology. 146: S-434. DOI: 10.1016/S0016-5085(14)61562-6 |
0.41 |
|
| 2014 |
Michels S, Eyck LT, Vanderpoel J, Lofland J, Ingham M, Uribe C, Denny L. Health care costs by level of adherence for infliximab patients with crohn’s disease Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.236 |
0.432 |
|
| 2014 |
Michels S, Eyck LT, Vanderpoel J, Lofland J, Ingham M, Uribe C, Denny L. Relative adherence across sites-of-care for infliximab patients with crohn’s disease Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.235 |
0.372 |
|
| 2014 |
Khetia A, Lofland J, Olson W, Wan G, Slaton T, Kozma C. Infliximab therapy adherence differences by site of care among patients with inflammatory bowel disease Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.234 |
0.398 |
|
| 2013 |
Lofland JH, Mallow P, Rizzo J. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis. Journal of Medical Economics. 16: 461-7. PMID 23445401 DOI: 10.3111/13696998.2013.775134 |
0.338 |
|
| 2013 |
Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 55: 393-401. PMID 23232289 DOI: 10.1097/Jom.0B013E31827Cba48 |
0.396 |
|
| 2013 |
Mallow P, Rizzo J, Queener M, Gathany T, Lofland J. Cost Per Clinical Remission and Clinical Response of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis American Journal of Gastroenterology. 108: S515-S516. DOI: 10.14309/00000434-201310001-01712 |
0.343 |
|
| 2013 |
Mallow P, Rizzo J, Queener M, Gathany T, Lofland J. Comparative Efficacy of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis American Journal of Gastroenterology. 108: S514. DOI: 10.14309/00000434-201310001-01707 |
0.322 |
|
| 2013 |
Mallow P, Rizzo J, Gathany T, Lofland J. P-060 Cost Per Clinical Response, Clinical Remission, and Mucosal Healing of Golimumab Among Patients with Ulcerative Colitis Inflammatory Bowel Diseases. 19: S52. DOI: 10.1097/01.Mib.0000438739.28909.B5 |
0.331 |
|
| 2013 |
Lofland J, Vanderpoel J, Nair K. P-058 Crohn’s Disease Patients with Early Biologic Treatment Versus Late Biologic Treatment Inflammatory Bowel Diseases. 19: S50-S51. DOI: 10.1097/01.Mib.0000438737.44157.E4 |
0.313 |
|
| 2013 |
Mallow P, Rizzo J, Gathany T, Lofland J. P-041 Cost per Clinical Response, Clinical Remission, and Mucosal Healing of Adalimumab, Golimumab, and Infliximab Among Patients with Ulcerative Colitis (UC) Inflammatory Bowel Diseases. 19: S41-S42. DOI: 10.1097/01.Mib.0000438682.16285.94 |
0.336 |
|
| 2013 |
David G, Gunnarsson CL, Lofland J, Goodney P, Siegel CA. Mo1362 Geographic Variation in Care of Patients With Inflammatory Bowel Disease Suggests Unequal Quality of Care in the United States Gastroenterology. 144: S-647. DOI: 10.1016/S0016-5085(13)62395-1 |
0.365 |
|
| 2013 |
Vanderpoel J, Schenkel B, Lofland J, DiBonaventura M, Gross H. Comparison of clinical and cost characteristics among patients with inflammatory bowel disease across different sites of care Value in Health. 16: A122. DOI: 10.1016/J.Jval.2013.03.585 |
0.424 |
|
| 2012 |
Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Digestive Diseases and Sciences. 57: 3080-91. PMID 22790905 DOI: 10.1007/S10620-012-2289-Y |
0.394 |
|
| 2012 |
Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. The Journal of Dermatological Treatment. 23: 240-54. PMID 21801089 DOI: 10.3109/09546634.2010.550911 |
0.392 |
|
| 2012 |
Siegel C, Lofland J, Naim A, Gollins J, Walls D, Rudder L, Reynolds C. Novel Statistical Approach to Determine Inflammatory Bowel Disease Patientsʼ Perspectives on Shared Decision Making: 1490 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-01490 |
0.327 |
|
| 2012 |
Siegel C, Lofland J, Naim A, Gollins J, Walls D, Rudder L, Reynolds C. Novel Statistical Approach to Determine Gastroenterologistsʼ Perspectives on Shared Decision Making for Patients with Inflammatory Bowel Disease: 1455 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-01455 |
0.361 |
|
| 2012 |
Siegel C, Lofland J, Naim A, Gollins J, Walls D, Rudder L, Reynolds C. Gastroenterologistsʼ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease: 1447 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-01447 |
0.36 |
|
| 2012 |
Vanderpoel J, Lofland J, Schmeichel C, Bos JVD, Gray T. Assessment of Infliximab Utilization Among Patients with Inflammatory Bowel Disease Across Different Sites of Care: 1446 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-01446 |
0.395 |
|
| 2012 |
Siegel C, Lofland J, Naim A, Rudder L, Reynolds C. Keys to Successful Implementation of Shared Decision Making in Inflammatory Bowel Disease: Recommendations from a Multi-Stakeholder Consensus Panel: 1444 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-01444 |
0.326 |
|
| 2012 |
Bolge S, Vanderpoel J, Eldridge H, Mody S, Lofland J, Ingham M. PSY58 Racial and Ethnic Differences in Patient Perceptions of Intravenous Biologic Therapy Among Currently Treated Patients With Immunology Conditions Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.592 |
0.305 |
|
| 2012 |
Vanderpoel J, Lofland J, Schenkel B, Dibonaventura M, Gross H. PSY24 Association of Patient Cost or Reimbursement Challenges With Health Care Resource Utilization, Quality of Life, and Work Productivity Among Patients With Inflammatory Bowel Disease Value in Health. 15: A102-A103. DOI: 10.1016/J.Jval.2012.03.558 |
0.442 |
|
| 2011 |
Lofland J, Gunnarsson C, Mallow P, Rizzo J, Feagan B. Cost-per-Responder Analysis of Infliximab Compared to Adalimumab Among Individuals with Moderate to Severe Ulcerative Colitis American Journal of Gastroenterology. 106: S418. DOI: 10.14309/00000434-201110002-01121 |
0.349 |
|
| 2011 |
Bolge S, Vanderpoel J, Eldridge H, Mody S, Lofland J, Ingham M. Patient Perceptions and Experiences with Sites of Care (SOCs) Among Patients with Immunology Conditions Currently Using Intravenous (IV) Biologic Therapy: 1114 The American Journal of Gastroenterology. 106. DOI: 10.14309/00000434-201110002-01114 |
0.327 |
|
| 2011 |
Vanderpoel J, Bolge S, Lofland J, Eldridge H, Mody S. Perceived Benefits of Intravenous (IV) Biologic Therapy Among Patients with Inflammatory Bowel Disease (IBD): 1104 The American Journal of Gastroenterology. 106. DOI: 10.14309/00000434-201110002-01104 |
0.389 |
|
| 2011 |
Vanderpoel J, Lofland J, Bolge S, Eldridge H, Mody S. Factors Influencing Medication and Site of Care (SOC) Selection Among Patients with Inflammatory Bowel Disease (IBD) Currently Receiving Intravenous (IV) Biologic Therapy: 1103 The American Journal of Gastroenterology. 106. DOI: 10.14309/00000434-201110002-01103 |
0.386 |
|
| 2011 |
Vanderpoel J, Lofland J, Bolge S, Schenkel B, Mody S, Kassed C, Ruetsch C, Tkacz J, Nicholls L, Tanner J. Infliximab utilization patterns within an alternate site of care setting among patients with Inflammatory Bowel Disease: P-73. Inflammatory Bowel Diseases. 17. DOI: 10.1097/00054725-201112002-00110 |
0.381 |
|
| 2011 |
Howe A, Lofland J, Freedman D. Self-reported disease comorbidities, frequency of flares, and medication treatment in individuals with Crohnʼs disease: Data from the National Health and Wellness Survey: P-69. Inflammatory Bowel Diseases. 17. DOI: 10.1097/00054725-201112002-00106 |
0.355 |
|
| 2011 |
Vanderpoel J, Lofland J, DiBonaventura M, Orlic Z. Association of treatment satisfaction with healthcare resource utilization, quality of life and work productivity among patients with Inflammatory Bowel Disease currently using biologic treatment Inflammatory Bowel Diseases. 17: S31-S32. DOI: 10.1097/00054725-201112002-00100 |
0.365 |
|
| 2011 |
Lofland J, Howe A, Waters H, Freedman D, Irvine J. Frequency and treatment of disease flares among individuals with Crohn's disease Inflammatory Bowel Diseases. 17. DOI: 10.1093/Ibd/17.Supplement1.S52B |
0.315 |
|
| 2011 |
Howe A, Lofland J, Waters H, Freedman D, Irvine J. Self-reported adherence, medication use, and switching patterns among individuals with Crohn's disease Inflammatory Bowel Diseases. 17. DOI: 10.1093/Ibd/17.Supplement1.S47 |
0.302 |
|
| 2011 |
Naim A, DiBonaventura M, Lofland J, Freedman D. PSY25 RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE Value in Health. 14: A63. DOI: 10.1016/J.Jval.2011.02.358 |
0.426 |
|
| 2010 |
Lofland J, Howe A, Waters H, Freedman D, Irvine JJ. Frequency and Treatment of Disease Flares among Individuals with Crohnʼs Disease: Data from the National Health and Wellness Survey American Journal of Gastroenterology. 105: S401. DOI: 10.14309/00000434-201010001-01107 |
0.351 |
|
| 2010 |
Lofland J, Howe A, Waters H, Freedman D, Irvine JE. Self-Reported Adherence, Medication Use, and Switching Patterns among Individuals with Crohnʼs Disease: Data from the National Health and Wellness Survey American Journal of Gastroenterology. 105: S401. DOI: 10.14309/00000434-201010001-01106 |
0.333 |
|
| 2010 |
Naim A, Lofland J, Freedman D, Annunziata K. Psy49 Impact Of Disease On Career Choices, Absenteeism, And Work Loss Among Individuals With Psoriasis In The United States Value in Health. 13. DOI: 10.1016/S1098-3015(10)73051-5 |
0.308 |
|
| 2010 |
Lofland J, Rizzo J, Gunnarsson C, Chen J, Waters H. PSY10 THE DIRECT MEDICAL COSTS OF PSORIASIS: EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA Value in Health. 13: A206-A207. DOI: 10.1016/S1098-3015(10)73012-6 |
0.332 |
|
| 2010 |
Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. PSY9 THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA Value in Health. 13: A206. DOI: 10.1016/S1098-3015(10)73011-4 |
0.387 |
|
| 2010 |
Bolge S, Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J. PMS11 THE DIRECT MEDICAL COSTS OF RHEUMATOID ARTHRITIS: EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA Value in Health. 13: A124. DOI: 10.1016/S1098-3015(10)72599-7 |
0.341 |
|
| 2010 |
Naim A, Lofland J, Bolge S, Rizzo J, Gunnarsson C, Chen J. PMS10 THE INDIRECT COSTS ASSOCIATED WITH ABSENTEEISM OF WORKING ADULTS WITH RHEUMATOID ARTHRITIS: EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA Value in Health. 13: A124. DOI: 10.1016/S1098-3015(10)72598-5 |
0.32 |
|
| 2010 |
Lofland J, Naim A, Rizzo JA, Gunnarsson CL, Chen J, Waters HC. M1033 The Direct Costs of Inflammatory Bowel Disease: Evidence From United States National Survey Data Gastroenterology. 138: S-317. DOI: 10.1016/S0016-5085(10)61459-X |
0.369 |
|
| 2007 |
Gagne JJ, Leas B, Lofland JH, Goldfarb N, Freitag F, Silberstein S. Quality of care measures for migraine: a comprehensive review. Disease Management : Dm. 10: 138-46. PMID 17590144 DOI: 10.1089/Dis.2007.103639 |
0.346 |
|
| 2006 |
Lofland JH, Frick KD. Workplace absenteeism and aspects of access to health care for individuals with migraine headache. Headache. 46: 563-76. PMID 16643549 DOI: 10.1111/J.1526-4610.2006.00404.X |
0.498 |
|
| 2006 |
Sciamanna CN, Nicholson RA, Lofland JH, Manocchia M, Mui S, Hartman CW. Effects of a Website designed to improve the management of migraines. Headache. 46: 92-100. PMID 16412156 DOI: 10.1111/J.1526-4610.2006.00312.X |
0.307 |
|
| 2006 |
Lofland JH, Frick KD. Effect of health insurance on workplace absenteeism in the U.S. workforce. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 48: 13-21. PMID 16404205 DOI: 10.1097/01.Jom.0000194150.06359.Ab |
0.505 |
|
| 2005 |
Lofland JH, Nash DB. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. Pharmacoeconomics. 23: 259-74. PMID 15836007 DOI: 10.2165/00019053-200523030-00006 |
0.33 |
|
| 2004 |
Wenzel R, Dortch M, Cady R, Lofland JH, Diamond S. Migraine headache misconceptions: barriers to effective care. Pharmacotherapy. 24: 638-48. PMID 15162898 DOI: 10.1592/Phco.24.6.638.34751 |
0.356 |
|
| 2004 |
Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 22: 165-84. PMID 14871164 DOI: 10.2165/00019053-200422030-00003 |
0.529 |
|
| 2003 |
Loeppke R, Hymel PA, Lofland JH, Pizzi LT, Konicki DL, Anstadt GW, Baase C, Fortuna J, Scharf T. Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 45: 349-59. PMID 12708138 DOI: 10.1097/01.Jom.0000063619.37065.E2 |
0.343 |
|
| 2002 |
Lofland JH, Frick KD. Publicly available US national surveys that capture lost productivity. Expert Review of Pharmacoeconomics & Outcomes Research. 2: 485-94. PMID 19807472 DOI: 10.1586/14737167.2.5.485 |
0.504 |
|
| 2002 |
Lofland JH, Lakhia PK. Migraine prophylaxis in managed care organizations: Unclear role in disease management programs Disease Management and Health Outcomes. 10: 489-494. DOI: 10.2165/00115677-200210080-00005 |
0.429 |
|
| 2001 |
Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics. 19: 917-25. PMID 11700778 DOI: 10.2165/00019053-200119090-00003 |
0.499 |
|
| 2001 |
Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine Headache. 41: 573-578. PMID 11437893 DOI: 10.1046/J.1526-4610.2001.041006573.X |
0.324 |
|
| 2001 |
Lofland JH, Kim SS, Batenhorst AS, Johnson NE, Chatterton ML, Cady RK, Kaniecki R, Nash DB. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine Mayo Clinic Proceedings. 76: 1093-1101. DOI: 10.4065/76.11.1093 |
0.417 |
|
| 2001 |
Girts T, Lofland J, O'Connor J. PPN12: DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE Value in Health. 4: 157-158. DOI: 10.1046/J.1524-4733.2001.40202-234.X |
0.33 |
|
| 2000 |
Lofland JH, Schaffer M, Goldfarb N. Evaluating health-related quality of life: Cost comparison of computerized touch-screen technology and traditional paper systems Pharmacotherapy. 20: 1390-1395. PMID 11079288 DOI: 10.1592/Phco.20.17.1390.34887 |
0.334 |
|
| 1999 |
Meletiche DM, Doshi D, Lofland JH. Medical Outcomes Study Short Form 36: a possible source of utilities? Clinical Therapeutics. 21: 2016-26; discussion . PMID 10890270 DOI: 10.1016/S0149-2918(00)86747-8 |
0.322 |
|
| 1999 |
Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective Archives of Internal Medicine. 159: 857-863. PMID 10219932 DOI: 10.1001/Archinte.159.8.857 |
0.414 |
|
| 1998 |
Yuran T, Schaffer M, Lofland J, Johnson N, Johnson K. MHA3 Comparison of Sumatriptan (IMITREX®) and Over-the-Counter (OTC) Medication Use According to Migraine Severity Value in Health. 1: 26. DOI: 10.1046/J.1524-4733.1998.1100253.X |
0.343 |
|
| Show low-probability matches. |